Lake, Diana E.

selected publications

First-in-Human Human Epidermal Growth Factor Receptor 2-Targeted Imaging Using ⁸⁹Zr-Pertuzumab PET/CT: Dosimetry and Clinical Application in Patients with Breast Cancer. Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 2017 Academic Article GET IT
Times cited: 132
A Pilot Study of Dose-Dense Paclitaxel With Trastuzumab and Lapatinib for Node-negative HER2-Overexpressed Breast Cancer. Clinical breast cancer. 2015 Academic Article GET IT
Times cited: 1
Do MRI and mammography reliably identify candidates for breast conservation after neoadjuvant chemotherapy?. Annals of surgical oncology. 2015 Academic Article GET IT
Times cited: 25
Phase II study of paclitaxel given once per week along with trastuzumab and pertuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2014 Academic Article GET IT
Times cited: 71
Endocrine therapy with or without inhibition of epidermal growth factor receptor and human epidermal growth factor receptor 2: a randomized, double-blind, placebo-controlled phase III trial of fulvestrant with or without lapatinib for postmenopausal women with hormone receptor-positive advanced breast cancer-CALGB 40302 (Alliance). Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2014 Academic Article GET IT
Times cited: 71
A phase II open-label study of ganetespib, a novel heat shock protein 90 inhibitor for patients with metastatic breast cancer. Clinical breast cancer. 2013 Academic Article GET IT
Times cited: 69
Randomized phase II trial of weekly vs. every 2 weeks vs. every 3 weeks nanoparticle albumin-bound paclitaxel with bevacizumab as first-line chemotherapy for metastatic breast cancer. Clinical breast cancer. 2013 Academic Article GET IT
Times cited: 25
Phase II trial of a novel capecitabine dosing schedule in combination with lapatinib for the treatment of patients with HER2-positive metastatic breast cancer. Breast cancer research and treatment. 2011 Academic Article GET IT
Times cited: 16
A feasibility study of bevacizumab plus dose-dense doxorubicin-cyclophosphamide (AC) followed by nanoparticle albumin-bound paclitaxel in early-stage breast cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 2011 Academic Article GET IT
Times cited: 25
Dose dense cyclophosphamide, methotrexate, fluorouracil is feasible at 14-day intervals: a pilot study of every-14-day dosing as adjuvant therapy for breast cancer. Clinical breast cancer. 2010 Academic Article GET IT
Times cited: 5
Phase II trial of weekly nanoparticle albumin-bound paclitaxel with carboplatin and trastuzumab as first-line therapy for women with HER2-overexpressing metastatic breast cancer. Clinical breast cancer. 2010 Academic Article GET IT
Times cited: 79
Feasibility trial of letrozole in combination with bevacizumab in patients with metastatic breast cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2009 Academic Article GET IT
Times cited: 42
A phase II trial of erlotinib in combination with bevacizumab in patients with metastatic breast cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 2008 Academic Article GET IT
Times cited: 110
Prolonged dose-dense epirubicin and cyclophosphamide followed by paclitaxel in breast cancer is feasible. Clinical breast cancer. 2008 Academic Article GET IT
Times cited: 6
High-dose chemotherapy with autologous stem cell rescue in stage IIIB inflammatory breast cancer. Anticancer research. 2008 Academic Article GET IT
Times cited: 5
A pilot study of dose-dense adjuvant paclitaxel without growth factor support for women with early breast carcinoma. Breast cancer research and treatment. 2008 Academic Article GET IT
Times cited: 11
The impact of sharing results of a randomized breast cancer clinical trial with study participants. Breast cancer research and treatment. 2008 Academic Article GET IT
Times cited: 18
Racial differences in clinical outcomes from metastatic breast cancer: a pooled analysis of CALGB 9342 and 9840--Cancer and Leukemia Group B. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2008 Academic Article GET IT
Times cited: 34
Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressors: final results of Cancer and Leukemia Group B protocol 9840. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2008 Academic Article GET IT
Times cited: 492
The safety of dose-dense doxorubicin and cyclophosphamide followed by paclitaxel with trastuzumab in HER-2/neu overexpressed/amplified breast cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2008 Academic Article GET IT
Times cited: 48
Pharmacokinetics and tolerability of exemestane in combination with raloxifene in postmenopausal women with a history of breast cancer. Breast cancer research and treatment. 2007 Academic Article GET IT
Times cited: 24
Increased dose density is feasible: a pilot study of adjuvant epirubicin and cyclophosphamide followed by paclitaxel, at 10- or 11-day intervals with filgrastim support in women with breast cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 2007 Academic Article GET IT
Times cited: 9
A phase II trial of gemcitabine in patients with metastatic breast cancer previously treated with an anthracycline and taxane. Clinical breast cancer. 2005 Academic Article GET IT
Phase II study of feasibility of dose-dense FEC followed by alternating weekly taxanes in high-risk, four or more node-positive breast cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 2004 Academic Article GET IT
Times cited: 28
Phase II trial of vinorelbine plus doxorubicin in relapsed small-cell lung cancer: CALGB 9332. American journal of clinical oncology. 2004 Academic Article GET IT
Times cited: 6
High-dose chemotherapy in breast cancer. Drugs. 2004 Information Resource GET IT
Times cited: 17
Aromatase inhibitors in breast cancer: an update. Cancer control : journal of the Moffitt Cancer Center. 2002 Information Resource GET IT
Times cited: 39
High-dose chemotherapy and stem cell transplantation for patients with stage IV breast cancer without clinically evident disease: correlation of CD34+ selection to clinical outcome. Bone marrow transplantation. 2000 Academic Article GET IT
Times cited: 5
A randomized study comparing standard versus moderately high dose megestrol acetate for patients with advanced prostate carcinoma: cancer and leukemia group B study 9181. Cancer. 2000 Academic Article GET IT
Times cited: 73
Single and double autotransplants for relapsing/refractory Hodgkin's disease: results of two consecutive trials. Bone marrow transplantation. 1997 Academic Article GET IT
Times cited: 23
Phase I clinical and laboratory evaluation of topotecan and cytarabine in patients with acute leukemia. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1997 Academic Article GET IT
Graft-versus-host disease. Possible higher risk for African American patients. Cancer. 1996 Academic Article GET IT
Times cited: 15
Fluconazole versus amphotericin B in the treatment of esophageal candidiasis in cancer patients. Chemotherapy. 1996 Academic Article GET IT
Times cited: 24
Factors influencing prognosis after dose-intensive therapy for recurrent or refractory Hodgkin's disease. Results of sequential trials: a case for treating patients with resistant disease. Annals of the New York Academy of Sciences. 1995 Academic Article GET IT
Peripheral blood mononuclear mobilization with sargramostim (GM-CSF). Progress in clinical and biological research. 1994 Academic Article GET IT
TMJ: a well-tolerated high-dose regimen for the adjuvant chemotherapy of high risk breast cancer. Journal of medicine. 1994 Academic Article GET IT
Times cited: 7

VIVO Weill Cornell Medical College

Diana E. Lake Associate Professor of Clinical Medicine

Publications

selected publications

Contact

full name

Phone

Publications

selected publications

Contact

full name